An in vivo pharmacological evaluation of pardoprunox (SLV308) - A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease

European Neuropsychopharmacology

Volumn 20, Issue 8, 2010, Pages 582-593

  Jones, C A ^a   Johnston, L C ^b   Jackson, M J ^b   Smith, L A ^b   van Scharrenburg, G ^a   Rose, S ^b   Jenner, P G ^b   McCreary, A C ^a  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

5 HT1A agonist; Dopamine D2 D3 partial agonist; MPTP; Pardoprunox (SLV308); Parkinson's

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; APOMORPHINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; PARDOPRUNOX; SEROTONIN 1A RECEPTOR; SULPIRIDE; BENZOXAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 1 AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; IN VIVO STUDY; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; AGONISTS; ANIMAL; CALLITHRIX; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; MOUSE; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; APOMORPHINE; BENZOXAZOLES; CALLITHRIX; DOPAMINE AGONISTS; FEMALE; MALE; MICE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIPERAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SULPIRIDE; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 77954034319     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.03.001     Document Type: Article

References (62)

1. Akai T., Yamaguchi M., Mizuta E., Kuno S. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann. Neurol. 1993, 33:507-511.
2. Arnt J., Hyttel J. Dopamine D2 agonists with high and low efficacies: differentiation by behavioural techniques. J. Neural. Transm. Gen. Sect. 1990, 80:33-50.
3. Bardin L., Kleven M.S., Barret-Grevoz C., Depoortere R., Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 2006, 31:1869-1879.
4. Baronti F., Mouradian M.M., Conant K.E., Giuffra M., Brughitta G., Chase T.N. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992, 42:1241-1243.
5. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
6. Bravi D., Davis T., Mouradian M., Chase T.N. Treatment of Parkinson's with the dopamine partial agonist EMD 49980. Mov. Disord. 1993, 8:195-197.
7. Bronzova, J., Sampaio, C., Hauser, R.A., Lang, A.E., Rascol, O., Theeuwes, A., Serge, V., van de Witte, S.V., van Scharrenburg, G., in press. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov. Disord.
8. Brücke T., Danielczyk W., Simányi M., Sofic E., Riederer P. Terguride: partial dopamine agonist in the treatment of Parkinson's disease. Adv. Neurol. 1987, 45:573-576.
9. Carlsson A. Treatment of Parkinson's with l-DOPA: the early discovery phase, and a comment on current problems. J. Neural. Transm. 2002, 109:777-787.
10. Clark D., Furmidge L.J., Petry N., Tong Z.Y., Ericsson M., Johnson D. Behavioural profile of partial D2 dopamine receptor agonists. 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology (Berl) 1991, 105:381-392.
11. Corsini G., Bonuccelli U., Rainer E., Del Zompo M. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J. Neural. Transm. 1985, 64:105-111.
12. Costall B., Naylor R.J. A comparison of circling models for the detection of antiparkinson activity. Psychopharmacologia 1975, 41:57-64.
13. Costall B., Naylor R.J., Pycock C. Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway. Eur. J. Pharmacol. 1976, 35:276-283.
14. Critchley P., Parkes D. Transdihydrolisuride in Parkinsonism. Clin. Neuropharmacol. 1987, 10:57-64.
15. 11C-WAY 100635 PET study. Neurology 2003, 60:601-605.
16. Fenton H.M., Leszczak E., Gerhardt S., Liebman J.M. Evidence for heterogeneous rotational responsiveness to apomorphine, 3-PPP and SKF 38393 in 6-hydroxydopamine-denervated rats. Eur. J. Pharmacol. 1984, 106:363-372.
17. Fox S.H., Chuang R., Brotchie J.M. Serotonin and Parkinson's disease: on movement, mood and madness. Mov. Disord. 2009, 24:1255-1266.
18. Gerber R., Altar C.A., Liebman J.M. Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) 1988, 94:178-182.
19. Giovannini P., Piccolo I., Genitrini S., Girotti F., Testa D., Scigliano G., Suchy I. Terguride in the treatment of Parkinson's disease: preliminary experience. Ital. J. Neurol. Sci. 1990, 11:381-385.
20. Glennon J.C., van Scharrenburg G., Ronken E., Hesselink M.B., Reinders J.H., van Der Neut M., Long S.K., Feenstra R.W., McCreary A.C. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 2006, 60:599-608.
21. Hagan J.J., Middlemiss D.N., Sharpe P.C., Poste G.H. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol. Sci. 1997, 18:156-163.
22. Heinrich J.N., Brennan J., Lai M.H., Sullivan K., Hornby G., Popiolek M., Jiang L.X., Pausch M.H., Stack G., Marquis K.L., Andree T.H. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur. J. Pharmacol. 2006, 552:36-45.
23. Hornykiewicz O. Brain monoamines and parkinsonism. Natl. Inst. Drug Abuse Res. Monogr. Ser. 1975, 3:13-21.
24. Ikoma Y., Akai T., Nakata Y., Hara K., Wachtel H., Yamaguchi M. Effects of terguride, an ergot alkaloid derivative, on the central nervous system: biochemical and behavioral studies. Nippon Yakurigaku Zasshi 1993, 102:113-129.
25. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In MPTP-treated primates, the selective 5-HT 1A receptor agonist (R)-(+)-8-OHDPAT inhibits l-DOPA induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther. 2006, 319:1225-1234.
26. 1B/D receptor agonist and antagonist administration on motor function in MPTP-treated common marmosets. Pharmacol. Biochem. Behav. 2007, 79:391-400.
27. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002, 58(S1):S1-S8.
28. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurologia 2004, 62(S1):S47-S55.
29. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease - a view of current knowledge and future opportunities. Mov. Disord. 2008, 23(S3):S585-S598.
30. Jenner P., Sheehy M., Marsden C.D. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol. 1983, 15(S2):277S-289S.
31. Jones C.A., McCreary A.C. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008, 55:1056-1065.
32. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 2001, 76:1346-1353.
33. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei. 2002, 54:133-137.
34. Koller W.C., Herbster G. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 1987, 37:723-727.
35. Krause W., Humpel M. Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. Eur. J. Drug Metab. Pharmacokinet. 1988, 13:185-194.
36. Krause W., Trager H., Kuhne G., Sauerbrev N., Graf K.G., Dorow R. Pharmacokinetics and endocrine effects of terguride in healthy subjects. Eur. J Clin. Pharmacol. 1990, 38:609-615.
37. Kuoppamäki M., Al-Barghouthy G., Jackson M.J., Smith L.A., Quinn N., Jenner P. l-DOPA dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J. Neural. Transm. 2007, 114:1147-1153.
38. Lange K.W., Loschmann P.A., Wachtel H., Horowski R., Jahnig P., Jenner P., Marsden C.D. Terguride stimulates locomotor activity at 2months but not 10months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur. J. Pharmacol. 1992, 212:247-252.
39. Löschmann P.A., Smith L.A., Lange K.W., Jahnig P., Jenner P., Marsden C.D. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl) 1992, 109:49-56.
40. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol. 2003, 179:90-102.
41. McCreary A.C., Glennon J.C., Ashby C.R., Meltzer H.Y., Li Z., Reinders J.H., Hesselink M.B., Long S.K., Herremans A.H., van Stuivenberg H., Feenstra R.W., Kruse C.G. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3- ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 2007, 32:78-94.
42. Millan M.J., Rivet J.M., Canton H., Le Marouille-Girardon S., Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J. Pharmacol. Exp. Ther. 1993, 264:1364-1376.
43. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.A., Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptors. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303:791-804.
44. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 2002, 303:805-814.
45. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verrièle L., Carpentier N., Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303:815-822.
46. Nomoto M., Jenner P., Marsden C.D. Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. Eur. J. Pharmacol. 1986, 121:123-128.
47. Olanow W., Schapira A.H., Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000, 23(S10):S117-S126.
48. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 2004, 27:58-62.
49. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
50. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-DOPA in the MPTP-treated marmoset. Mov. Disord. 1998, 13:234-241.
51. Pérez-Otaño I., Herrero M.T., Oset C., De Ceballos M.L., Luquin M.R., Obeso J.A., Del Río J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res. 1991, 567:127-132.
52. Pirtosek Z., Merello M., Carlsson A., Stern G. Preclamol and Parkinsonian fluctuations. Clin. Neuropharmacol. 1993, 16:550-554.
53. Pirtosek Z., Merello M., Carlsson A., Stern G. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Adv. Neurol. 1996, 69:535-540.
54. Rollema H., Mastebroek D., Wikstrom H., Svensson K., Carlsson A., Sundell S. Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics. J. Med. Chem. 1986, 29:1889-1895.
55. Ruggieri S., Stocchi F., Baronti F., Viselli F., Horowski R., Lucarelli C., Agnoli A. Antagonist effect of terguride in Parkinson's disease. Clin. Neuropharmacol. 1991, 14:450-456.
56. Saigusa T., Tuinstra T., Koshikawa N., Cools A.R. High and low responders to novelty: effects of a catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. Neuroscience 1999, 88:1153-1163.
57. Schapira A.H., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., Hengerer B., Hirsch E., Jenner P., Le Novere N., Obeso J.A., Schwarzschild M.A., Spampinato U., Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 2006, 5:845-854.
58. Smith L., De Salvia M., Jenner P., Marsden C.D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated common marmosets. Mov. Disord. 1996, 11:125-135.
59. 3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Neuropharmacology 2006, 29:112-125.
60. Tamminga C.A., Cascella N.G., Lahti R.A., Lindberg M., Carlsson A. Pharmacologic properties of (-)-3PPP (preclamol) in man. J. Neural. Transm. Gen. Section. 1992, 88:165-175.
61. Tricklebank M.D., Forler C., Fozard J.R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 1984, 106:271-282.
62. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigro-striatal system. Brain Res. 1970, 24:485-493.